Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251630 | 1.00 | ATM (0.42) | ATMPOLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL4254075 | 1.00 | ATM (0.42) | ATMPOLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL4258297 | 1.00 | ATM (0.42) | ATMPOLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL4258841 | 1.00 | ATM (0.42) | ATMPOLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL4258300 | 1.00 | ATM (0.42) | ATMPOLBCYP3A4CYP2C19CHRM2 | |
| SCHEMBL468848 | 1.00 | ATM (0.42) | ATMPOLBCYP3A4CYP2C19CHRM2 | |
| Lactic Acid SCHEMBL15522846 | 0.89 | TP53 (0.38) | ATMPOLB | |
| SCHEMBL17154184 | 0.87 | ATM (0.34) | ATMPOLBCHRM2CHRM4CHRM5 | |
| SCHEMBL11770755 | 0.83 | PIK3CA (0.37) | ATMPOLB | |
| SCHEMBL22208124 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117536-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | Beiersdorf AG (DE) | 2009-11-18 | — | — | EP | claimed |
| WO-2008101693-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | claimed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2024055011-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | TEAM MEDICAL, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-114096559-A | Engineered IGA antibodies and methods of use thereof | 蒂嘉特克斯公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-113365667-A | Nucleic acid constructs comprising gene editing multiple sites and uses thereof | 艾欧生物科学公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-110651046-A | Nucleic acid constructs comprising gene editing multiple sites and uses thereof | 艾欧生物科学公司 | 2020-01-03 | — | — | CN | disclosed |
| EP-2946779-A1 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | Beiersdorf AG (DE) | 2015-11-25 | — | — | EP | disclosed |
| EP-2932958-A1 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | Beiersdorf AG (DE) | 2015-10-21 | — | — | EP | disclosed |
| EP-2124934-B1 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | BEIERSDORF AG (DE) | 2015-04-08 | — | — | EP | disclosed |
| EP-2124934-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | Beiersdorf AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| EP-2117536-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | Beiersdorf AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008101692-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACETYLHYDROXYPROLINE | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101693-A2 | COSMETIC AND PHARMACEUTICAL APPLICATIONS OF N-ACYLATED AMINO ACIDS AND STRUCTURALLY RELATED COMPOUNDS | BEIERSDORF AG (DE) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115595-A1 | MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY | RBM22, HNRNPUL2, HNRNPUL1 | ATM 3828/4885POLB 414/4885CYP3A4 4874/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ATM 3816/4885POLB 712/4885CYP3A4 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.